A MEK-independent role for CRAF in mitosis and tumor progression

Nature Medicine

Volumn 17, Issue 12, 2011, Pages 1641-1645

  Mielgo, Ainhoa ^a   Seguin, Laetitia ^a   Huang, Miller ^a   Camargo, Maria Fernanda ^a   Anand, Sudarshan ^a   Franovic, Aleksandra ^a   Weis, Sara M ^a   Advani, Sunil J ^b   Murphy, Eric A ^a   Cheresh, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; ANTINEOPLASTIC AGENT; AURORA A KINASE; KG 5; L 779450; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; PACLITAXEL; POLO LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; UNCLASSIFIED DRUG; ZM 33637;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CENTROMERE; CENTROSOME; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; MITOSIS; MITOSIS SPINDLE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMETAPHASE; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUMOR BIOPSY; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CENTROSOME; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; KINETOCHORES; MAP KINASE KINASE 1; MICE; MICE, NUDE; MITOSIS; MITOTIC SPINDLE APPARATUS; NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RAF; SIGNAL TRANSDUCTION;

MURINAE; MUS;

EID: 84856097810     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2464     Document Type: Article

References (37)

1. Wellbrock C., Karasarides M. & Marais R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5, 875-885 (2004). (Pubitemid 39486539)
2. Dhillon A.S., Hagan S., Rath O. & Kolch W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290 (2007). (Pubitemid 46763021)
3. Bollag G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
4. Flaherty K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
5. Joseph E.W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 107, 14903-14908 (2010).
6. King A.J. et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66, 11100-11105 (2006). (Pubitemid 46009933)
7. Tsai J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 105, 3041-3046 (2008). (Pubitemid 351723664)
8. Yang H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527 (2010).
9. Hatzivassiliou G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
10. Heidorn S.J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
11. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M. & Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
12. Murphy E.A. et al. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRβ/B-RAF. Proc. Natl. Acad. Sci. USA 107, 4299-4304 (2010).
13. Alavi A., Hood J.D., Frausto R., Stupack D.G. & Cheresh D.A. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301, 94-96 (2003). (Pubitemid 36801568)
14. Alavi A.S., Acevedo L., Min W. & Cheresh D.A. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res. 67, 2766-2772 (2007). (Pubitemid 46548965)
15. McGlynn L.M. et al. Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin. Cancer Res. 15, 1487-1495 (2009).
16. Mikula M. et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J. 20, 1952-1962 (2001). (Pubitemid 32397397)
17. Weber C.K., Slupsky J.R., Kalmes H.A. & Rapp U.R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595-3598 (2001). (Pubitemid 32694968)
18. Borysov S.I., Cheng A.W. & Guadagno T.M. B-Raf is critical for MAPK activation during mitosis and is regulated in an M phase-dependent manner in Xenopus egg extracts. J. Biol. Chem. 281, 22586-22596 (2006).
19. Borysov S.I. & Guadagno T.M. A novel role for Cdk1/cyclin B in regulating B-raf activation at mitosis. Mol. Biol. Cell 19, 2907-2915 (2008).
20. Borysova M.K., Cui Y., Snyder M. & Guadagno T.M. Knockdown of B-Raf impairs spindle formation and the mitotic checkpoint in human somatic cells. Cell Cycle 7, 2894-2901 (2008).
21. Cui Y., Borysova M.K., Johnson J.O. & Guadagno T.M. Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells. Cancer Res. 70, 675-684 (2010).
22. Cui Y. & Guadagno T.M. B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells. Oncogene 27, 3122-3133 (2008). (Pubitemid 351693167)
23. Malumbres M. & Barbacid M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 17, 60-65 (2007). (Pubitemid 46109297)
24. Nigg E.A. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2, 21-32 (2001). (Pubitemid 33676958)
25. Taylor S. & Peters J.M. Polo and Aurora kinases: Lessons derived from chemical biology. Curr. Opin. Cell Biol. 20, 77-84 (2008).
26. Macurek L. et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 455, 119-123 (2008).
27. Petronczki M., Lenart P. & Peters J.M. Polo on the rise-from mitotic entry to cytokinesis with Plk1. Dev. Cell 14, 646-659 (2008). (Pubitemid 351622626)
28. Seki A., Coppinger J.A., Jang C.Y., Yates J.R. & Fang G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 320, 1655-1658 (2008). (Pubitemid 351931258)
29. Knauf J.A. et al. Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. J. Biol. Chem. 281, 3800-3809 (2006). (Pubitemid 43847804)
30. Luo J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848 (2009).
31. McInnes C. et al. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat. Chem. Biol. 2, 608-617 (2006). (Pubitemid 44610345)
32. Santamaria A. et al. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol. Biol. Cell 18, 4024-4036 (2007). (Pubitemid 47519493)
33. Steegmaier M. et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol. 17, 316-322 (2007). (Pubitemid 46241881)
34. Strebhardt K. Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy. Nat. Rev. Drug Discov. 9, 643-660 (2010).
35. Hüser M. et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J. 20, 1940-1951 (2001). (Pubitemid 32397396)
36. Hindley A. & Kolch W. Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J. Cell Sci. 115, 1575-1581 (2002). (Pubitemid 34520587)
37. Kamata T. et al. BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res. 70, 8475-8486 (2010).